IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v13y2015i2p207-222.html
   My bibliography  Save this article

The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997–2010

Author

Listed:
  • Frank Lichtenberg

Abstract

The estimates imply that approximately two-thirds of the 2000–2010 decline in premature mortality was due to pharmaceutical innovation. If no NCEs had been launched in Slovenia during 1992–2003, the age-standardized number of cancer deaths in 2008 would have been 12.2 % higher. The NCEs launched in Slovenia during 2003–2009 are estimated to have reduced the number of hospital discharges in 2010 by 7 %. If we assume that pharmaceutical expenditure was the only type of expenditure affected by pharmaceutical innovation, the cost per life-year saved was €3,953, which is well below even the lowest estimates of the value of a life-year saved. Moreover, 85 % of the increase in drug expenditure may have been offset by a reduction in hospital expenditure; therefore. the cost per life-year saved may have been only €611. Copyright Springer International Publishing Switzerland 2015

Suggested Citation

  • Frank Lichtenberg, 2015. "The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997–2010," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 207-222, April.
    • Handle: RePEc:spr:aphecp:v:13:y:2015:i:2:p:207-222
    DOI: 10.1007/s40258-014-0144-3
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s40258-014-0144-3
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s40258-014-0144-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Joseph E. Aldy & W. Kip Viscusi, 2008. "Adjusting the Value of a Statistical Life for Age and Cohort Effects," The Review of Economics and Statistics, MIT Press, vol. 90(3), pages 573-581, August.
    2. Frank R. Lichtenberg, 2014. "Has Medical Innovation Reduced Cancer Mortality?," CESifo Economic Studies, CESifo Group, vol. 60(1), pages 135-177.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Hassan Heidari & Arash Refah Kahriz & Yousef Mohammadzadeh, 2019. "Stock market behavior of pharmaceutical industry in Iran and macroeconomic factors," Economic Change and Restructuring, Springer, vol. 52(3), pages 255-277, August.
    2. Nahila Justo & Jonas Nilsson & Beata Korytowsky & Johan Dalen & Terri Madison & Alistair McGuire, 2020. "Retrospective observational cohort study on innovation in oncology and progress in survival: How far have we gotten in the two decades of treating patients with advanced non-small cell lung cancer as ," PLOS ONE, Public Library of Science, vol. 15(5), pages 1-12, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Lichtenberg, Frank R. & Tatar, Mehtap & Çalışkan, Zafer, 2014. "The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010," Health Policy, Elsevier, vol. 117(3), pages 361-373.
    2. Jeon, Sung-Hee & Pohl, R. Vincent, 2019. "Medical innovation, education, and labor market outcomes of cancer patients," Journal of Health Economics, Elsevier, vol. 68(C).
    3. Martin Gaynor & Nirav Mehta & Seth Richards-Shubik, 2023. "Optimal Contracting with Altruistic Agents: Medicare Payments for Dialysis Drugs," American Economic Review, American Economic Association, vol. 113(6), pages 1530-1571, June.
    4. Aldy, Joseph, 2019. "Birds of a Feather: Estimating the Value of Statistical Life from Dual-Earner Families," Working Paper Series rwp19-013, Harvard University, John F. Kennedy School of Government.
    5. Herrera-Araujo, Daniel & Rochaix, Lise, 2020. "Does the Value per Statistical Life vary with age or baseline health? Evidence from a compensating wage study in France," Journal of Environmental Economics and Management, Elsevier, vol. 103(C).
    6. Patrick Carlin & Brian E. Dixon & Kosali I. Simon & Ryan Sullivan & Coady Wing, 2022. "How Undervalued is the Covid-19 Vaccine? Evidence from Discrete Choice Experiments and VSL Benchmarks," NBER Working Papers 30118, National Bureau of Economic Research, Inc.
    7. Hala Abou-Ali & Hesham El-Azony & Heba El-Laithy & Jonathan Haughton & Shahid Khandker, 2010. "Evaluating the impact of Egyptian Social Fund for Development programmes," Journal of Development Effectiveness, Taylor & Francis Journals, vol. 2(4), pages 521-555.
    8. Bishop, Kelly C. & Kuminoff, Nicolai V. & Mathes, Sophie M. & Murphy, Alvin D., 2024. "The marginal cost of mortality risk reduction: Evidence from housing markets," Journal of Urban Economics, Elsevier, vol. 139(C).
    9. Nicolò Gatti & Beatrice Retali, 2021. "Fighting the spread of Covid-19 : was the Swiss lockdown worth it?," IdEP Economic Papers 2101, USI Università della Svizzera italiana.
    10. James K. Hammitt & Peter Morfeld & Jouni T. Tuomisto & Thomas C. Erren, 2020. "Premature Deaths, Statistical Lives, and Years of Life Lost: Identification, Quantification, and Valuation of Mortality Risks," Risk Analysis, John Wiley & Sons, vol. 40(4), pages 674-695, April.
    11. repec:aei:rpaper:1008589856 is not listed on IDEAS
    12. W. Kip Viscusi, 2018. "Pricing Lives: International Guideposts for Safety," The Economic Record, The Economic Society of Australia, vol. 94(S1), pages 1-10, June.
    13. Johannes Schoder & Peter Zweifel, 2011. "Flat-of-the-curve medicine: a new perspective on the production of health," Health Economics Review, Springer, vol. 1(1), pages 1-10, December.
    14. W. Viscusi, 2008. "How to value a life," Journal of Economics and Finance, Springer;Academy of Economics and Finance, vol. 32(4), pages 311-323, October.
    15. Brajer, Victor & Mead, Robert W. & Xiao, Feng, 2008. "Health benefits of tunneling through the Chinese environmental Kuznets curve (EKC)," Ecological Economics, Elsevier, vol. 66(4), pages 674-686, July.
    16. David Boisclair & Yann Décarie & François Laliberté-Auger & Pierre-Carl Michaud & Carole Vincent, 2018. "The economic benefits of reducing cardiovascular disease mortality in Quebec, Canada," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
    17. Thomas DeLeire & Shakeeb Khan & Christopher Timmins, 2013. "Roy Model Sorting And Nonrandom Selection In The Valuation Of A Statistical Life," International Economic Review, Department of Economics, University of Pennsylvania and Osaka University Institute of Social and Economic Research Association, vol. 54(1), pages 279-306, February.
    18. Nicolò Gatti & Beatrice Retali, 2021. "Saving lives during the COVID-19 pandemic: the benefits of the first Swiss lockdown," Swiss Journal of Economics and Statistics, Springer;Swiss Society of Economics and Statistics, vol. 157(1), pages 1-21, December.
    19. Meera Kotagal & Kiran J Agarwal-Harding & Charles Mock & Robert Quansah & Carlos Arreola-Risa & John G Meara, 2014. "Health and Economic Benefits of Improved Injury Prevention and Trauma Care Worldwide," PLOS ONE, Public Library of Science, vol. 9(3), pages 1-7, March.
    20. David E. Bloom & Michael Kuhn & Klaus Prettner, 2022. "Modern Infectious Diseases: Macroeconomic Impacts and Policy Responses," Journal of Economic Literature, American Economic Association, vol. 60(1), pages 85-131, March.
    21. Hammitt, James K. & Herrera-Araujo, Daniel, 2018. "Peeling back the onion: Using latent class analysis to uncover heterogeneous responses to stated preference surveys," Journal of Environmental Economics and Management, Elsevier, vol. 87(C), pages 165-189.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:13:y:2015:i:2:p:207-222. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.